AUTL
Income statement / Annual
Last year (2025), Autolus Therapeutics plc's total revenue was $75.56 M,
an increase of 646.68% from the previous year.
In 2025, Autolus Therapeutics plc's net income was -$287.53 M.
See Autolus Therapeutics plc,s key income statements, including revenue, expenses, profit, and income.
| Period |
FY-2025
|
FY-2024
|
FY-2023
|
FY-2022
|
FY-2021
|
FY-2020
|
FY-2019
|
FY-2018
|
FY-2017
|
FY-2016
|
| Period Ended |
12/31/2025 |
12/31/2024 |
12/31/2023 |
12/31/2022 |
12/31/2021 |
12/31/2020 |
12/31/2019 |
09/30/2018 |
09/30/2017 |
09/30/2016 |
| Operating Revenue |
$75.56 M |
$10.12 M |
$1.70 M |
$6.19 M |
$1.51 M |
$1.72 M |
$2.91 M |
$1.05 M |
$1.69 M |
$1.21 M |
| Cost of Revenue |
$96.37 M
|
$141.02 M
|
$0.00
|
$0.00
|
$0.00
|
$134.89 M
|
$105.42 M
|
$48.30 M
|
$1.01 M
|
$478.00 K
|
| Gross Profit |
-$21.03 M
|
-$130.90 M
|
$1.70 M
|
$6.19 M
|
$1.51 M
|
-$133.17 M
|
-$102.51 M
|
-$47.25 M
|
$684.00 K
|
$734.00 K
|
| Gross Profit Ratio |
-0.28
|
-12.93
|
1
|
1
|
1
|
-77.65
|
-35.25
|
-45.2
|
0.4
|
0.61
|
| Research and Development Expenses |
$117.69 M
|
$158.14 M
|
$130.48 M
|
$117.35 M
|
$110.84 M
|
$134.99 M
|
$105.62 M
|
$24.64 M
|
$16.01 M
|
$10.44 M
|
| General & Administrative Expenses |
$0.00
|
$0.00
|
$46.75 M
|
$31.90 M
|
$31.87 M
|
$34.97 M
|
$39.45 M
|
$16.85 M
|
$9.10 M
|
$5.15 M
|
| Selling & Marketing Expenses |
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
| Selling, General & Administrative Expenses |
$131.87 M
|
$0.00
|
$46.75 M
|
$31.90 M
|
$31.87 M
|
$34.97 M
|
$39.45 M
|
$16.85 M
|
$9.10 M
|
$5.15 M
|
| Other Expenses |
$10.84 M
|
-$47.61 M
|
$4.17 M
|
-$166.00 K
|
-$823.00 K
|
$0.00
|
$0.00
|
$3.97 M
|
-$46.00 K
|
-$26.00 K
|
| Operating Expenses |
$260.41 M
|
$110.53 M
|
$181.40 M
|
$149.09 M
|
$141.88 M
|
$169.96 M
|
$145.07 M
|
$41.48 M
|
$25.11 M
|
$15.59 M
|
| Cost And Expenses |
$357.00 M
|
$251.55 M
|
$181.40 M
|
$149.09 M
|
$141.88 M
|
$304.85 M
|
$250.49 M
|
$41.48 M
|
$25.11 M
|
$15.59 M
|
| Interest Income |
$18.98 M
|
$32.36 M
|
$13.51 M
|
$1.71 M
|
$262.00 K
|
$536.00 K
|
$2.54 M
|
$4.12 M
|
$84.00 K
|
$75.00 K
|
| Interest Expense |
$36.76 M
|
$9.29 M
|
$45.07 M
|
$8.91 M
|
$1.11 M
|
$0.00
|
$0.00
|
$12.67 K
|
$0.00
|
$0.00
|
| Depreciation & Amortization |
$9.84 M
|
$7.72 M
|
$6.57 M
|
$7.42 M
|
$8.46 M
|
$5.57 M
|
$4.56 M
|
$1.71 M
|
$1.01 M
|
$478.00 K
|
| EBITDA |
-$271.60 M |
-$233.07 M |
-$156.77 M |
-$132.24 M |
-$132.48 M |
-$162.58 M |
-$137.40 M |
-$50.32 M |
-$22.41 M |
-$13.90 M |
| EBITDA Ratio |
-3.59
|
-23.03
|
-92.33
|
-21.35
|
-87.91
|
-94.8
|
-47.25
|
-48.14
|
-13.24
|
-11.47
|
| Operating Income Ratio |
-3.72
|
-23.86
|
-105.83
|
-23.07
|
-93.15
|
-176.75
|
-85.14
|
-55.04
|
-13.83
|
-11.86
|
| Total Other Income/Expenses Net |
-$15.41 M
|
$22.29 M
|
-$28.70 M
|
-$5.67 M
|
-$1.66 M
|
$136.88 M
|
$138.89 M
|
$6.91 M
|
$38.00 K
|
$49.00 K
|
| Income Before Tax |
-$296.85 M
|
-$219.13 M
|
-$208.40 M
|
-$148.57 M
|
-$142.04 M
|
-$166.26 M
|
-$108.69 M
|
-$36.33 M
|
-$23.38 M
|
-$14.33 M
|
| Income Before Tax Ratio |
-3.93
|
-21.65
|
-122.73
|
-23.99
|
-94.25
|
-96.94
|
-37.38
|
-34.75
|
-13.81
|
-11.82
|
| Income Tax Expense |
$1.97 M
|
$1.53 M
|
-$19.00 K
|
$272.00 K
|
$58.00 K
|
-$24.16 M
|
$15.16 M
|
-$5.21 M
|
-$3.65 M
|
-$1.78 M
|
| Net Income |
-$287.53 M
|
-$220.66 M
|
-$208.38 M
|
-$148.84 M
|
-$142.10 M
|
-$142.09 M
|
-$123.85 M
|
-$31.11 M
|
-$19.73 M
|
-$12.55 M
|
| Net Income Ratio |
-3.81
|
-21.8
|
-122.72
|
-24.03
|
-94.29
|
-82.85
|
-42.59
|
-29.76
|
-11.65
|
-10.35
|
| EPS |
-1.08 |
-0.87 |
-1.2 |
-1.57 |
-1.97 |
-2.76 |
-2.88 |
-0.99 |
-1.43 |
-0.91 |
| EPS Diluted |
-1.08 |
-0.87 |
-1.2 |
-1.57 |
-1.97 |
-2.76 |
-2.88 |
-0.99 |
-1.43 |
-0.91 |
| Weighted Average Shares Out |
$266.14 M
|
$255.16 M
|
$173.94 M
|
$94.99 M
|
$72.08 M
|
$51.56 M
|
$43.07 M
|
$31.56 M
|
$13.78 M
|
$13.78 M
|
| Weighted Average Shares Out Diluted |
$266.14 M
|
$255.16 M
|
$173.94 M
|
$94.99 M
|
$72.08 M
|
$51.56 M
|
$43.07 M
|
$31.56 M
|
$13.78 M
|
$13.78 M
|
| Link |
|
|
|
|
|
|
|
|
|
|
